Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Shares Outstanding (Diluted Average) (2021 - 2025)

Serina Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $10.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 52.63% year-over-year to $10.3 million; the TTM value through Sep 2025 reached $10.3 million, up 52.63%, while the annual FY2024 figure was $7.4 million, 0.11% changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $10.3 million at Serina Therapeutics, up from $9.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $37.9 million in Q1 2022 and bottomed at $1079.0 in Q4 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $7.4 million (2023), against an average of $9.5 million.
  • The largest YoY upside for Shares Outstanding (Diluted Average) was 681178.96% in 2023 against a maximum downside of 80.41% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $37.7 million in 2021, then tumbled by 100.0% to $1079.0 in 2022, then skyrocketed by 681178.96% to $7.4 million in 2023, then rose by 0.11% to $7.4 million in 2024, then surged by 40.49% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Shares Outstanding (Diluted Average) are $10.3 million (Q3 2025), $9.9 million (Q2 2025), and $9.8 million (Q1 2025).